GVA Earnings

GVA reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 1.43B against an estimate of 1.48B, resulting in a -3.38% surprise. The EPS was 2.7, surpassing the expected 2.53 by 6.72%. The stock experienced a -3.28% price change on the earnings day and a -0.25% change over the next five days, reflecting market reactions to the results.

Following GVA's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by -3.28% on the day of the release. Over the subsequent five days, it saw a -0.25% change. Historically, GVA's stock price tends to shift by an average of -3.47% in the 10 days leading up to earnings and 5.69% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate GVA's annual revenue to reach 792.72M, while the EPS is projected at -0.42. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GVA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GVA's stock price typically moves by -3.47% in the 10 days before its earnings and 5.69% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.42 and revenue of 792.72M.

The earnings call reveals a mixed performance with significant declines in the antigen business, disappointing gross margins, and uncertainty in Chinese sales resumption. Despite some positive developments in the QAPs business and cost control, the lack of profitability forecast for Q4 and unclear management responses in the Q&A section contribute to a negative outlook. The market cap suggests a moderate reaction, leading to a prediction of a -2% to -8% stock price movement.